Skip to main content English

Detail

Sazan Rasul
Priv.-Doz. Dr.med.univ. Sazan Rasul, PhD

Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine)
Position: Senior physician

ORCID: 0000-0003-2898-3232
T +43 1 40400 58742
sazan.rasul@meduniwien.ac.at

Further Information

Keywords

Metabolism; Molecular Imaging; Oncology; Radioactive Tracers

Research interests

My research focuses on helping to understand the relevance of various cellular and metabolic pathways for proper organ function. Utilizing small amounts of a radioactively labeled substance, it is possible to image various receptors and a variety of peptides potentially involved in the metabolism and pathology of diseases and tumors in the field of nuclear medicine in which I work. Therefore, via molecular imaging targeting receptors and biochemical processes specifically involved in disease etiology and tumor pathogenesis, nuclear medicine plays a pivotal role in the field of endocrinology, oncology, cardiology, and brain metabolism.

Using the similar approach, but employing specific radionuclides suitable for therapy, radionuclide-labeled therapies have been developed that specifically target certain receptors that are overexpressed in certain disorder and tumor cells, thereby systemically destroying the local tumor and its distant metastases; a process called targeted theranostics.

Techniques, methods & infrastructure

Positron Emission Tomography-Computed Tomography/Magnetic Resonance Imaging employing various radio-labeled peptides targeting cells and specific receptors responsible for tumor and cellular metabolism at the molecular level.

Selected publications

  1. Rasul, S. et al., 2019. Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. European Journal of Nuclear Medicine and Molecular Imaging, 47(3), pp.713–720. Available at: http://dx.doi.org/10.1007/s00259-019-04584-1.
  2. Rasul, S. et al., 2020. Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 48(5), pp.1650–1657. Available at: http://dx.doi.org/10.1007/s00259-020-05082-5.
  3. Rasul, S. et al., 2021. Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers, 13(10), p.2489. Available at: http://dx.doi.org/10.3390/cancers13102489.
  4. Rasul, S. et al., 2018. [18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. European Journal of Nuclear Medicine and Molecular Imaging, 45(12), pp.2159–2169. Available at: http://dx.doi.org/10.1007/s00259-018-4045-9.
  5. Rasul, S. et al., 2020. Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using 18F-FDG PET/MRI. BMJ Open Diabetes Research & Care, 8(1), p.e001135. Available at: http://dx.doi.org/10.1136/bmjdrc-2019-001135.